Grifols (GRFS) Change in Account Payables (2010 - 2020)
Grifols' (GRFS) quarterly Change in Account Payables came in at -$25.7 million in Q1 2020, up 53.91% YoY from -$16.7 million in Q2 2019, and up 67.14% on a QoQ basis from -$78.2 million in Q4 2019.
Grifols (GRFS) Change in Account Payables (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Change in Account Payables data on file, last reported at -$25.7 million in Q1 2020.
- Quarterly Change in Account Payables rose 53.91% year-over-year to -$25.7 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$155.5 million (down 134.7% YoY) and the FY2025 annual result came in at $109.4 million, up 253.09% from the prior year.
- Change in Account Payables climbed to -$25.7 million in Q1 2020, from -$78.2 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $81.5 million in Q4 2016 to a low of -$78.2 million in Q4 2019.
- A 5-year average of -$5.2 million and a median of $4.2 million in 2018 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2016 — Change in Account Payables jumped 128.83% — and 2019, when it plunged 1957.3%.
- Tracing GRFS's Change in Account Payables over 5 years: stood at $81.5 million in 2016, then slumped by 40.67% to $48.3 million in 2017, then tumbled by 91.29% to $4.2 million in 2018, then sank by 1957.3% to -$78.2 million in 2019, then jumped by 67.14% to -$25.7 million in 2020.
- The last three Change in Account Payables figures came in at -$25.7 million (Q1 2020), -$78.2 million (Q4 2019), and -$55.8 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -70.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 18.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -25.70 Mn |
| Mar 31, 2020 | -25.70 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Dec 31, 2016 | 81.49 Mn |
| Dec 31, 2016 | 81.49 Mn |